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Background: This is the second article related to a review of the literature based on data from national cystic fibrosis (CF) registries up to June
2008 and covering a total of 115 studies. It focuses on two topics: neonatal screening (NS) and nutritional status, with particular reference to
growth.
Methods: Ten papers meeting the inclusion criteria were found on the topic of NS and its impact on the course of the disease, and were analyzed
according to a dedicated grid. The issue of nutrition was addressed by 14 studies, analyzed according to similar criteria.
Results: Most of the studies report benefits of early diagnosis by NS, albeit to variable degrees. The benefits were assessed in terms of better
nutritional status and growth, but also in terms of lower overall morbidity rate as compared to subjects diagnosed by symptoms. The main biases
of these studies, which partly undermine the validity of their results, are also analyzed.
A part of our analysis on nutrition/growth is dedicated to the identification of the most suitable parameters to define malnutrition: in children
older than two years the body mass index percentile (BMIp) appears to be the most sensitive and significantly associated with respiratory function.
Better nutritional status and satisfactory growth appear to be associated with better lung function and lower risk of death. The relationship between
nutritional status and socio-economic status is also of interest.
Conclusions: CF registry studies support the outcome of cohort observational studies i.e. that pre-symptomatic early diagnosis is beneficial,
especially in terms of nutritional status and growth. Studies on nutrition indicate that good nutritional status is associated with better respiratory
function and prognosis. Regarding methods, the need emerged to manage potential biases of this kind of non randomized studies, resorting to
suitable statistical techniques, such as matching and stratification and, above all, to multivariate methods able to provide estimates adjusted for the
main covariates tested.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Patient registry; Newborn screening; Growth; Nutrition; Epidemiology⁎ Corresponding author.
E-mail address: gianni.mastella@azosp.vr.it (G. Mastella).
1569-1993/$ - see front matter © 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.jcf.2009.11.002
76 D. Salvatore et al. / Journal of Cystic Fibrosis 9 (2010) 75–83Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
3. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.1. Neonatal screening (NS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
3.2. Nutritional status and growth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
4. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 821. Introduction
Disease registries are epidemiological tools able to guarantee
continuous and comprehensive monitoring of individual data of
patients suffering from a disease in a certain geographical region.
Their overall objective is to collect accurate information on the
disease. In the ideal scenario registries should be able to integrate
clinical trials in the description of clinical events and healthcare
needs, as well as in the assessment of results in real world clinical
practice. Their usual key inclusion criterion is the certainty of the
diagnosis of the patient to be included in the registry. Their
strength is the possibility of putting together sufficiently large case
series for the assessment and interpretation of many aspects of the
disease via stratification for one or more important variables.
Cystic fibrosis (CF) appears to be a disease model that is well
suited for a global assessment via patient registries, as it is a
chronic, progressive disease, subject to changes over time. Its
clinical expression varies, partly on account of its genotype,
several body systems are involved following complications and
its treatment is complex and heterogeneous, requiring costly
therapies tailored to specific needs of patients. However, CF is a
relatively rare disease (e.g. when compared to diseases such as
asthma) so that an individual centre may have relatively few
patients. At an individual country level or at a global level,
therefore, the care of CF patients needs to be coordinated for
maximum benefit. To do that, we need to accumulate and analyze
data on its natural history for as many patients as possible: this is
the property and function of the CF patient registries.
In 2006 the Italian Cystic Fibrosis Research Foundation
organized a training course entitled “The Italian Cystic Fibrosis
Registry: a resource for teaching, awareness-raising and health-
care organization”. As final result of the course, the participants
carried out an analysis of the scientific literature produced with
data from the national registries of CF patients. The objectives of
the analysis have been described in a previous paper [1]: in
essence, to search for and analyze the scientific literature derived
fromCF registry data, understand which clinical issues have been
properly addressed, providing correct answers and determine
which are still in need of further research.
In this second paper we address a) neonatal screening (NS)
and b) nutritional status, with particular reference to growth.
The diagnosis of CF based on symptoms may occur after a
notable delay. It is now well known that a NS programme can
resolve the issue, enabling a diagnosis in the first weeks of life.
At present there is no conclusive evidence that the earlydiagnosis of CF by means of NS has important long-term
consequences both in terms of morbidity and mortality. This
state of affairs may be due to mistakes in the interpretation of
results obtained from historical cohorts, not from randomized
trials. On the other hand, a systematic review of 5 studies (2
Randomized Controlled Trials and 3 observational studies) [2]
reports that the risk of death is 5 to 10% lower in the cohorts of
patients screened than in those who were not screened.
Regarding nutritional issues, changes in nutritional status
and the resulting delay in growth are very important complica-
tions in CF patients. They are due to many factors, including
pancreatic insufficiency and inadequate calorie intake in the
presence of increased metabolic needs, also due to the possible
occurrence of chronic pulmonary infection or diabetes mellitus.
A critical issue is the correct definition of malnutrition and,
consequently, the criteria and parameters used for its measure-
ment. The definition of malnutrition has undergone substantial
changes over time due to differences in classification and the
numerous parameters that have been suggested for its
measurement [3]. An increased body of literature indicates
that nutritional and oxygen status during development can
induce both immediate and long-term alterations in the structure
and function of the lung, where the alveoli, relatively primitive
at birth, have to increase in number by septation such that
3 million alveoli become 300 million by the age of 8 years
[4,5]. The relationship between improvement in nutritional
status on one hand and in pulmonary function and survival on
the other is very important in clinical and prognostic terms. The
study of this relationship is a priority for CF registries.
2. Methods
We summarize the procedure of literature analysis already
described in the previous article [1]. We included primary studies
that used data collected via a formally instituted, at least national
patient registry to verify research hypotheses in our review. The
studies based on unofficial registries (cohort studies) were
excluded, as well as those based on local registries or non CF
registries, and those that used the registry data as controls or for
RCT recruitment. We also excluded reviews, comments,
editorials and letters; articles in which registries were only
quoted; annual reports; duplications of already published papers.
A search in Pubmed and Embase up to the cutoff date June
30, 2008 was carried out with the following strategy: (“Cystic
fibrosis” [MESH] AND (“Registry”[MESH]) OR registr$)).
Table 1
Neonatal screening studies.
Ref 1st author Year Registry Focus Patients
6 Wang 2001 CFF USA Association between early CF diagnosis and acquisition of
Pseudomonas aeruginosa, in the first decade of life.
3625
7 Wang 2002 CFF USA Impact of early diagnosis on pulmonary function 3625
8 McCormick 2002 UKCFD Composition of the CF population attending UK centres in terms
of age, gender, age at diagnosis, genotype and ethnicity.
5274
9 Lai 2004 CFF USA Relationship between mode of diagnosis and initial presentation
and lung disease and survival
27,703
10 Lai 2005 CFF USA Impact of age and condition at the time of diagnosis on survival 27,692
11 Sims 2005 UKCFD Influence of early identification on CF outcome 1134
12 Accurso 2005 CFF USA Complication and hospitalization rates by mode of diagnosis. 2566
13 Sims 2005 UKCFD Effects of increased therapeutic intervention in screened people 1134
14 Sims 2007 UKCFD Potential savings in treatment costs attributable to newborn screening 1134
15 Sims 2007 UKCFD Comparison of outcome and treatment between early and late
clinically diagnosed, and NS diagnosed
1167
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registries were interviewed using a questionnaire. The search in
the two main data banks (PubMed and Embase) made it possible
to identify 193 articles, 90 of whichmet the inclusion criteria. The
lists of publications provided by the main registries completed the
data retrieved in the bibliographic search: 133 articles were
pointed out, of which 50 had already been identified by the data
bank search; of the remaining 83, 25 fulfilled the inclusion
criteria. A total of 115 studies were thus analyzed, using a grid
developed by the participants attending the training course [1].3. Results
Out of the 115 studies included in our review [1], 10 focused
on NS [5 came from the United States (US) register of the CF
Foundation (CFF) and 5 from the UK register] (Table 1).
Fourteen studies addressed aspects related to growth and
nutritional status [8 from the US-CFF registry, 2 from theTable 2
Nutrition and growth studies.
Ref 1st author Year Registry Focus
18 Corey 1988 CFF USA; Canada Comparison of 2 CF clinic
pulmonary function, and su
19 Lai 1998 CFF USA Assessment of growth statu
various anthropometric indi
20 Zhang 2004 CFF USA Agreement on the use of%I
21 Lai 1999 CFF USA; Canada Assessment of growth statu
23 Zemel 2000 CFF USA Relationship between growt
24 Lai 2000 CFF USA Evaluation of the long-term
clinical trial of treatment wi
26 Lai 2000 CFF USA Comparison of malnutrition
ileus and those diagnosed th
27 Schechter 2001 CFF USA Impact of low socio-econom
28 Beker 2001 CFF USA Usefulness of height for age
29 Steinkamp 2002 Germany Relationship between nutrit
30 Konstan 2003 ESCF USA Influence of growth and nu
31 Kastner-Cole 2005 UKCFD Relationship between overw
32 Wiedemann 2007 Germany Performance of BMIp comp
as measures for nutritional f
33 Stallings 2008 CFF USA Evidence-based recommend
pancreatic enzyme and growCanadian and US registries used together, 1 from the US
Epidemiologic Study on Cystic Fibrosis (ESCF) programme, 1
from the UK registry and, finally, 2 from the German registry]
(Table 2).3.1. Neonatal screening (NS)
Published studies tend to be very heterogeneous in terms of
their approach to the issues and the outcomes selected to verify
the research hypotheses.
An observational study of the US-CFF registry [6] on more
than 3000 subjects subdivided into 4 homogeneous patient
groups, stratified for time of diagnosis and presence of symptoms
(early vs late diagnosis and presence vs absence of symptoms)
assessed the risk of Pseudomonas aeruginosa (PA) acquisition
longitudinally in the first 10 years of life in the 4 groups. The
Kaplan Meier analysis, applied to each diagnostic group, showed
that the risk of acquiring PAwas not significantly different amongPatients
populations with respect to growth,
rvival
499 at Boston; 534 at Toronto
s and identification of malnutrition with
cators
13,116
BW and BMIp for screening malnutrition 22,303
s of CF population in USA and Canada 29,610 USA; 3145 Canada
h, nutritional status, and pulmonary function 968
growth of children who participated in a
th steroids
224
between patients with meconium
rough NS
82
ic status on mortality and morbidity 2390
percentile as a predictor of survival 2273
ion and lung function 3298
tritional status on pulmonary function 931
eight/obesity and lung function 2987
ared with standard anthropometric indexes,
ailure
4577
ations for energy intake, dosing for
th monitoring
22,700
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more than 3000 patients followed up for a long time and that it was
very thorough in adjusting the analysis for possible confounding
factors (such as country of origin and year of birth). The authors
point out some possible biases themselves (such as the
observational nature of the study, possible selection biases and
variability among centres in sampling and culture techniques).
Another paper by the same authors [7] using the same data
assessed the hypothesis that respiratory function is better in the
cohorts who have been diagnosed more recently (children aged
6 to 10 years) amongst CF subjects diagnosed early via NS. The
results suggested that the hypothesis may be true, but did not
reach statistical significance. Furthermore, the same potential
biases of the previous study apply here. Moreover, the role of
some factors that may impair respiratory function independently
was not assessed (bacterial colonization, air pollution, asthma,
exercise, acute infections). The conclusion was that longer
follow-up might enable better understanding of the impact of
early diagnosis on respiratory function.
An assessment of the frequency distribution of the main
mutations in various ethnic groups of the UK population [8]
suggested which was the most suitable diagnostic molecular
analysis kit to achieve the highest detection rate in aNS programme
that uses also CFTRmutation analysis in a multiethnic population,
such as the one in the UK.
However, the studies focused mainly on the hypothesis that
certain baseline risk factors may be associated with major
outcomes, such as survival and pulmonary outcomes. The first
example is the study by Lai [9], on 27,703 patients reported to
the 1986–2000 CF Foundation Registry, in which the clinical
presentation of the disease, gender, CFTR genotype and
diagnostic method (assessed in 4 different groups: meconium
ileus [MI], neonatal/prenatal screening, positive family history
and symptoms other than MI) were related to such outcomes,
showing greater survival in the screened group than in the
others. Subjects diagnosed by NS were usually born in more
recent years, so the comparison between screened and non
screened subjects could be prone to bias unless adjustment is
made for the differences in year of birth, in view of the
progressive improvement in care throughout the years. The
effect of NS is also influenced by the difference in programmes
in the various geographical regions of birth; this made it
difficult to separate the impact of regional differences in quality
of care from the effect of NS itself. Another paper by Lai et al.
[10] reached a similar conclusion: it supports the advantage of
an NS programme in terms of survival by means of a complex
model of statistical analysis that controls the differences
between screened and non screened subjects, by adjusting for
various confounding factors, including year of birth.
In 2005 a study from the UK CF database [11] showed the
benefits of NS, expressed as the achievement of a significantly
greater median height and a reduction in morbidity (better clinical
and radiological score, fewer infections due to PA) in screened
patients as compared to controls matched for age and genotype.
These results suggest that even within the context of modern care
at specialized centres, which all patients have access to, the early
diagnosis by NS appears to offer global advantages.The paper byAccurso et al. [12] analyzed the new diagnoses of
CF, identified by the US-CFF registry between 2000 and 2002, to
determine the correlation between mode of diagnosis and
abnormalities (length b3rd percentile, body weight b3rd
percentile, culture positive for PA, abnormally low plasma levels
of electrolytes and proteins and oedema) and the hospitalization
rate. The patients diagnosed byNS had a lower number of adverse
outcomes than the other groups. Also in this case the bias
associated with a possible overestimate of the benefit in the
groups diagnosed byNS due to the inclusion ofmild forms cannot
be excluded (although the genotype is accounted for).
Other two studies derived from the UK database address other
potential social and economic benefits of NS [13,14]. The first of
these studies [13] assessed the effect, within 3 months from birth,
of diagnosis by NS as compared to diagnosis by symptoms on the
extent of care provided in the two CF populations diagnosed after
1994. Based on the analysis of the data from 41CF centres and 12
healthcare services, the hypothesis was tested that the extent of
care may be an indicator of the effect of early diagnosis on the
course of pulmonary disease. Indeed, it was observed that the
patients diagnosed byNS required fewer therapeutic interventions
and, overall, less intensive therapy (adjusting for variables, such
as age, genotype, geographical region and social status) before the
age of six. Between the age of 7 and 9 this group required less
antibiotic therapy by intravenous route, especially if the patients
were not colonized by PA. In the event of an intermittent or
chronic infection due to PA, the differences between screened and
not screened subjects were no longer detectable. Also the
correction for genotype did not change the outcome.
A more recent study of the same British group [14] analyzed
the costs of care of CF patients diagnosed on the basis of
symptoms as compared to those diagnosed by NS. It reached the
conclusion that, at least in the first ten years of life, the cost of
treatment in the group of screened patientswas significantly lower
than the cost of treatment in the group of patients diagnosed by
symptoms. This result is associated with the advantage of being
able to implement prophylactic care in asymptomatic patients
diagnosed early. These savings would balance the higher costs
required for the implementation of the NS programme. The
authors acknowledge some limitations of their study, such as the
fact that they cover only 75% of the CF population, the inclusion
of patients diagnosed by symptoms also during the first 2 months
of life, failure to record short courses of therapy, pancreatic
extracts and nutritional therapy. Another limitation appears to be
considering the Scottish population similar to that in the whole of
the UK. However, these limitations do not seem to invalidate the
overall significance of the study, which supports clear advantages
of early diagnosis by NS. These conclusions are supported by
another study by the same authors [15], which once again shows
the efficacy of NS in promoting better nutritional status
(expressed as a height z-score) and lowering morbidity, in terms
of a higher clinical score and reducing long-term therapy, as
compared to diagnosis by symptoms, especially when it occurs
after the first two months of life. This study highlights that
increasing the window of diagnosis from 2 months to 3 months or
beyond increases the proportion of patients with poor long-term
growth. On the basis of these results, the authors propose, and find
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diagnosis of CF is redefined to a diagnosis made within 2 months
of birth, with respect to the current definition of 3 months of birth,
created by Shwachman in the 1970s [17].
3.2. Nutritional status and growth
Attention was directed towards nutrition in CF patients by the
findings of the Canadian and US patient registries [18]. Indeed,
better nutritional, anthropometric and survival indices were
reported at the CF centre in Toronto (Canada) than at the centre
in Boston (US). The study focused on the description of the
characteristics of the patients in the two centres and their outcome
in order to detect factors contributing to any differences in
outcome (growth, pulmonary function and survival). Treatment at
the two centres differed considerably in terms of dietary regimen
and pancreatic enzyme supplements: low lipid diet and low
enzyme intake in Boston vs high lipid diet and high doses of
pancreatic enzymes in Toronto. Additional putative causes of the
differences in patient survival between the two centres were
differences in access to healthcare and differences in the
prevalence and severity of bacterial and/or viral infections.
The definition of malnutrition has undergone substantial
changes over time due to the differences in classification and the
numerous parameters that have been suggested for its
measurement. In 1998 Lai et al. compared a series of nutritional
parameters to establish which was the most sensitive [19].
Weight for age percentile (WAP) and height for age percentile
(HAP) would be the most appropriate indices to identify CF
children at risk of malnutrition, with the classical definitions of
stunting (height percentile b5th) and wasting (weight percentile
b5th). The percentage of ideal body weight for height (%IBW),
which is considered normal if N85%, appears not to be
sufficiently sensitive for pubertal patients, especially in males
over 11.5 years of age or taller than 145 cm. For this reason the
use of the weight/height ratio percentile (WHP) is recom-
mended for children aged 0–2 years and the body mass index
percentile (BMIp) from 2 to 18 years of age. The study shows
that malnutrition occurs mainly during the first year of life and
in adolescents: during these periods therapeutic efforts designed
to promote optimal growth should be increased.
Zhang et al. [20] confirmed that the IBW% underestimates
the severity of malnutrition in short children (b25th centile)
and, vice versa, overestimates it in tall children (N75th centile)
as compared to BMIp. This discrepancy increases with age,
even when stature deviates considerably from the mean.
Another study by Lai et al. in 1999 [21] compared the course
of growth between Canada and the US once more. The study
supports the concept that the main factor responsible for the
difference recorded in the 1980s [18] was the difference in
nutrition, with recovery and elimination of the difference after
the introduction in the US of the same dietary and pancreatic
supplement regimen provided in Toronto. Indeed, mean body
weight and height were at about 30th percentile in CF children
in the US and 4 to 5 percentiles more in CF children in Canada,
but the percentages as compared to ideal body weight (104%)
were similar in the two populations. Adults had a similar meanheight (about 37th percentile), but the Canadians were
significantly better in terms of body weight (26th percentile
vs 21st) and percentage of ideal body weight (93% vs 90%). In
any case, the differences between the two populations were not
as marked as the previous ones. The authors stress the
importance of bearing in mind centre variability, as there can
be major differences among centres in terms of patient
characteristics and therapy. Furthermore, additional importance
is ascribed to the fact that different growth standards were used
in the two studies, pointing out how important it is to attempt to
choose the same methods to assess growth in terms of weight
and height in order to obtain homogeneous results in different
studies. Another problem about this study is the missing
evaluation of parental heights: both parents of CF patients have
been reported to be shorter than controls [22]. This phenomenon
affecting target height, if confirmed, could be an important bias
and therefore maybe the reference standards have yet another
problem that is rarely addressed.
Zemel et al. [23] analyzed a cohort of children 5 to 8 years of
age, all with pancreatic insufficiency, extracted from the US
registry. First of all the study showed that growth and respiratory
functionwere not stable in the prepubertal period; moreover, there
was a significant difference between the two genders in favour of
males. Finally, various statistical models showed that there was a
significant association between FEV1 decline and nutritional
parameters, after adequate correction for factors, such as gender
and hospitalizations, suggesting therefore that an adequate
nutritional intervention could influence respiratory function.
Naturally, also treatment may affect growth. The study by Lai
et al. published in 2000 [24] assessed the long-term effects of
cortisone treatment in a cohort of the patients within a completed
trial [25]. The study showed that growth slowed down to such an
extent that it reduced the final height of 4 cm in prepubertal males,
but not in females. If this phenomenon materially affects the
outcome of disease is unknown.
Among the other factors that could have an impact on
nutritional status, meconium ileus (MI) appears to have a particular
influence: CF patients diagnosed with MI who have had an ileal
resection appear to be more malnourished than patients diagnosed
by NS, notwithstanding adequate calorie intake. The difference
observed is so large that it has been hypothesized that patients with
MI may have a distinct and more severe phenotype of CF [26].
Also socio-economic status plays a role in the clinical
expression of CF. In order to calculate the impact of these
factors, Schechter et al. [27] analyzed theMedicaidCF population
reported in the US-CFF registry. The study reported that the
disease was more severe in patients of low socio-economic status,
starting from the first years of life, with lower values of body
weight, height and FEV1 and a 3.6 higher risk of death. It is likely
that poor socio-economic status is associated with a series of
unfavourable environmental influences, such as internal and
external pollution, exposure to passive smoking, greater incidence
of viral respiratory infections, greater individual and familial
stress, with lower adherence to therapeutic programmes. The
impact of socio-economic status is so evident that the authors
suggest that it should be considered a confounding factor in all
clinical trials.
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observed that children of both genders with a height below the
5th percentile between the age of 5 and 7 years had a much
higher relative risk of death than taller children [28]. The results
were clear-cut, but the analysis does not identify any of the
possible factors responsible for the stunting phenomenon.
In 2002 the German CF Quality Assurance (CFQA),
studying a cohort of more than 3000 CF patients, confirmed
the correlation between nutrition, pulmonary function and
clinical course, highlighting how a normal nutritional state is
associated with a reduction in the prevalence of PA pulmonary
infections and improved respiratory function. Malnutrition
associated with the presence of PA significantly accelerates
the progression of pulmonary damage as compared to
malnourished patients not colonized by PA [29].
The article by Konstan et al. [30] assessed the correlation
between growth and nutritional status with pulmonary function
in CF children less than six years old. The study recorded that
malnourished CF children at the age of three years had a
reduction in pulmonary function at the age of six, therefore
suggesting aggressive and early nutritional interventions during
the first years of life.
In the case series presented by Kastner-Cole et al. in 2005
[31] the prevalence of overweight and obesity in CF patients
homozygous for the F508del mutation and their relationship to
pulmonary function are assessed. In this UK series, 9% of
patients were overweight and 1% were obese according to their
BMI values. In children the authors show a beneficial effect of
high BMI on FEV1 even at BMI z-score levels of 1 to 2. In
adults, on the other hand, a positive relationship to FEV1 is
observed only up to BMI value of 23 kg/m2. In conclusion,
results of this paper do not support calorie restriction in
relatively overweight children with CF, as is currently advised
for the general paediatric population. Caloric counselling may
be advisable for young adults with CF and a BMI above 23 kg/
m2 in view of the absence of a further beneficial effect of BMI
on lung function and the potentially increased risks of a
chronically raised BMI in adulthood (i.e. heart disease, high
blood pressure).
The study by Wiedemann et al. [32] stresses the usefulness
of BMIp in children older than 2 years. BMIp resulted to be the
most sensitive parameter among the anthropometric indices in
detecting malnutrition early. The proportion of malnourished
and short patients is higher during the first two years of life and
gradually diminishes in both genders, but continues to increase
in adults.
In 2008 Stallings et al. [33], after a systematic review of the
literature, analyzed the population of the US registry with the
objective of providing recommendations based on evidence of
efficacy and on registry data. In particular, the use of BMI was
recommended, whereas the use of the IBW% method was not.
The objective was set to maintain BMIp at the 50th centile or
more in all patients between 2 and 20 years of age. The use of
WHP was recommended for children below two years of age:
this parameter should be kept stable or N50th centile at the
patient's second birthday. Finally, the maintenance of a BMI of
22 for women and 23 for men was recommended for adults agedover 20 years, asking them not to lose weight voluntarily. These
recommendations, which were defined as “Registry data-based”
by the authors, derive from the observation that BMIp, in the
analyses conducted in more than 22,000 recorded patients, is
more sensitive and better related to changes in pulmonary
function.
4. Discussion
The analysis of the literature from the CF registries offers a
lot of information on issues related both to NS and nutritional
status and growth, but raises also methodological issues and
suggests that additional studies should be carried out.
Regarding screening, efficacy studies carried out on registry
retrospective data are obviously non randomized observational
studies which, as such, are exposed to the risk of many kinds of
biases. Subjects diagnosed by NS were probably born more
recently, so the comparison of screened vs non screened
subjects without adjustment for year of birth could be subject to
bias, in view of the improvement in care over time. On the other
side, recent UK data [34] show no significant difference in
survival in the most recent 10 year cohorts, presumably related
to steadily improving clinical management of CF and to the
striking reduction in deaths in the first year of life, associated
with the survival of infants with MI resulting from improved
neonatal management.
Furthermore, NS is somewhat related to the geographical
region of birth and it is therefore difficult to separate regional
differences in quality of care from the screening effect, when
national population data are reviewed, such as registry
populations. The large size of the patient registry does not
adequately compensate for differences in care and other factors
among regions and centres (centre bias), such as variability in
microbiologic sampling and culture techniques [6,7], genetic
[8], environmental, social factors [27] and lifestyles.
Finally, age at diagnosis may vary according to the severity
of symptoms and may therefore cause diagnostic bias [9].
Patients diagnosed on the basis of symptoms have a higher
event rate during the first years of life than those who were
diagnosed by NS. However, the lower morbidity rate in the
latter could be due to the fact that they are often affected by
milder forms of the disease, which usually are diagnosed later in
life. From this point of view it is important to point out that an
attempt to use the same genotype when comparing across
registries is the only currently feasible way of teasing potential
differences due to milder forms of the disease. It is imperative
that homozygous F508del are studied/compared as they are the
most prevalent. It is equally important to point out that even
patients with the same genotype can have vastly different
outcomes, so a spread of outcomes even in this genetically
homogeneous group is to be expected.
An interesting observation is that non Caucasian patients
(e.g. Asians) who have greater difficulty in accessing care and
are in worse clinical conditions, because of a variety of reasons,
such as cultural, socio-economic, nutritional, dietary and
language barriers [35], do not experience a diagnostic delay
as compared to Caucasian populations in the same region in the
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patients have a very poor outcome, it might be that focusing on
screening with respect to this poor sub-group might give an
early indication of future benefits of NS.
The biases related to the lack of homogeneity of compared
groups do not enable any definitive conclusions, considering also
the changes in quality of care over the years and the differences in
care among centres [9,10,12]. On the other hand, regarding the
main issues raised related to the efficacy of NS in CF, overall, the
registry studies provide indications that nutritional status and
morbidity may improve in screened patients [11–13,15], whereas
it is difficult to establish the impact on pulmonary function [7] and
on survival [9,10] with certainty, as confounding factors (age and
mode of diagnosis, quality and intensity of therapeutic pro-
grammes) make the interpretation of survival curves and relative
risks in the various cohorts studied difficult. Furthermore, the lack
of availability of respiratory function tests for pre-school children
makes objective evaluations difficult until after the age of 5 or
6 years.
Therefore, prospective controlled trials designed to assess
the impact of NS in the long-term, allowing for confounding
factors, are to be encouraged. Furthermore, the development
and dissemination of respiratory function tests in infants
and children below 5 years of age could provide important
information on the expression of CF pulmonary involvement
in children diagnosed by NS as compared to symptomatic
children.
Studies on growth assess a strategically decisive element,
such as nutritional status, presumably at the centre of the
pathogenetic chain in CF. It is in some ways unsurprising the
importance of nutrition for lung development and the
deleterious effects of persistent inflammation on lung growth
[4,5]. Supporters of NS should argue with claims such as “the
nutritional status of screened children is better; patients with
better nutritional status have better pulmonary function; better
pulmonary function is associated with longer survival”. Thus,
studies attempting to identify the most suitable factors for the
detection of malnutrition and its monitoring over time
[19,30,32] in terms of sensitivity and specificity and predictive
power are of particular importance. Indeed, the difficulty in
choosing an appropriate parameter to define malnutrition in CF
patients is critical. The current consensus, supported by a
systematic review [33], is that BMIp is the most reliable index
for the assessment of nutritional status in CF patients in children
older than two years, whereas WHP is more advisable under the
age of two years. It is therefore possible to associate nutritional
data with respiratory function data. BMIp is more sensitive and
more closely associated with FEV1 than other parameters, such
as IBW%. On the other side, the correlation between BMI and
pulmonary function tests is related to the inclusion of height in
the BMI formula and fails to take stunting (i.e. stature b5th
percentile) into consideration. Weight for age, height for age
and weight for height percentiles are nowadays parameters
useful to evaluate nutritional status [19] and are related to
pulmonary function [30].
Regarding the relationship between nutritional status and
prognosis suggested by the observation of outcomes inCanadian patients in Toronto as compared to those in Boston
[18], the message is to pay more attention to growth and
nutritional status, especially during the critical years, such as the
very first years of life, when formation of alveoli by septation is
intense, and puberty [19,30], in view of the likelihood that these
parameters are related to respiratory conditions [29,30,33]. This
emphasizes the factors that could promote better nutrition and
enables the detection and early correction of factors determining
malnutrition.
The therapeutic approach to malnutrition based on dietary
advice and/or long-term clinical nutrition is still under evaluation.
The study byCorey [18]may be considered amodel of fruitful use
of registry data because the lipid-rich dietary regimen together
with more pancreatic supplements became routine treatment for
CF following the evidence that it collected; the repetition of the
comparison 10 years later seems to confirm the validity of this
approach [21].
Counselling and interventions to support weight gain in CF
constitute an important aspect of clinical management. With
such strategies, however, there exists the potential for excessive
weight gain in some patients [31]. Moreover the nutritional
intervention could not reflect the situation that might pertain
when NS takes effect: the absence of severe infections in a
screened group might lower the nutritional requirements of
these patients.
Meconium ileus is a factor that could have a negative impact
on nutritional status [26]. US data, however, are contradicted by
other studies where MI did not represent an additional risk
factor for the patient's life [36].
Other elements require further studies. Interactions with socio-
economic status [27] observed in the US should be assessed also
in countries with different healthcare systems based on universal
public access. The presence of PA in the airways [29] should be
studied together with environmental and socio-economic factors,
as well as in the presence of complications that occur more
frequently with age (e.g. diabetes, musculoskeletal disorders,
renal disorders, etc.).
From a methodological point of view most studies, after
having explored differences in means, medians or proportions
amongst groups, attempt to adjust for confounding factors. As
the studies are not randomized, attempts should be made to
control any potential biases by appropriate techniques, such as
matching [8,14], stratification [6,27] and, above all, using
multivariate models [9,10,15,20,26,27,30,32], able to provide
estimates adjusted for the main covariates, such as gender, age,
age at diagnosis, genotype, clinical variables, calendar year, etc.
5. Conclusions
The analysis of the literature from CF registries, which
usually collect clinical and demographic data adequately and
continually update the information, identified many studies that
attempted to estimate the effects of NS on morbidity and
mortality rates. These studies tend to support the concept that
children diagnosed as early as possible (i.e. by NS) (the concept
of “early” being now less than 2 months of age) [15,16], and
therefore submitted to early and intensive treatment, especially
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function at least up to the age of 8–10 years. On the contrary,
evidence is still lacking on advantages of NS in terms of
pulmonary disease progression and long-term survival.
Regarding nutritional issues, the studies have clarified the
reliability of the various nutritional and growth indices in CF
patients. Focusing on growth and nutritional status appears to be
of great importance, especially during the first years of life and
puberty. The objective of associating nutritional and respiratory
data appears to be crucial. The usefulness of tools such as dietary
advice and long-term clinical nutrition is still under evaluation.
The studies based on the registries offer information of great
importance for clinicians and epidemiologists. However, they
also highlight the need for prospective controlled clinical trials
with adequate follow-up periods supporting the research
hypotheses that derive from registry studies, which are mostly
non controlled and invariably retrospective.
In terms of accumulating sufficient information to audit and
research the disease and its natural history, some means of
recording, collating and analyzing data for as many patients as
possible is required and the data collected by the various
registries have to be homogeneous.
This would increase the number of eligible patients and
therefore the quantity of data and information that can be used to
analyze selected issues in detail. Such issues include the prognostic
impact of NS and the correct management of nutritional status, in
view of its potential influence on respiratory function and,
ultimately, on quality of life and survival.References
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